Her primary clinical focus is on melanoma and cutaneous oncology. Dr. Boland serves on the Surgical Oncology Program Committee for the Dana Farber/Harvard Surgical Oncology Fellowship, the Harvard Surgery Research Day Committee, the Resident Advisory Committee and the MGH Executive Committee on Research Subcommittee for Research Review. Her laboratory is currently focused on characterization of molecular and immunological changes that occur during immunotherapy and the identification of circulating biomarkers of cancer. As a Broad Institute affiliate, she is establishing analytic pipelines for blood-based biomarker development in cancer to transition novel biomarkers to CLIA-based assays and to prospectively validate their use through clinical trials.